http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009067767-A3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_00a421ab71bd49a451d0a49d23a082c7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_60392f2ee4c16094e66c1721241d7f85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_58c11d1cf8b33f217e1c8f6633c0808f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a2961e0f09109e3630323a1bddd4823f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d5fb2e6abb87198795fd3cf686be8046 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3ae61138a22d4a50dba467678c7872ee |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2008-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef1d37248539e99d2ada15d86457b1cf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00fc7a0654f8457e8bff94bf96f3e8d2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_812ac6b7c8538ee88b8e427b56e1424e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03e401ff425997ff09a67e35c4eea2b8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e87bce0a5966e2791fbb1103abf330f7 |
| publicationDate | 2010-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2009067767-A3 |
| titleOfInvention | Targeted radiotherapy |
| abstract | The present invention concerns a therapeutically labeled napthodianthrone or phenanthro[1,10,9,8-opqra]perylene-7,14-dione compound, which comprises a chemical element or an isotope that has an unstable nucleus and emits radiation during its decay to a stable form sufficient to destroy neighboring cells or tissues for use in a targeted radiotherapy to enhance curability of a warm-blooded animal that has been subjected to a necrosis-inducing antitumor therapy. A particular advantage of present invention is that viable rim resistant to a necrosis-inducing antitumor therapy such as vascular targeting agent (VTA) can be supplemented by one single or repeated doses of a therapeutically radiolabeled small molecule necrosis-avid chemical compound treatment to enhance the curability. Examples of necrosis inducing therapies are for instance minimally invasive tumor ablations applied chemically by percutaneous injection of ethanol or acetic acid, or physically by cryotherapy, microwave, focused ultrasound, interstitial laser therapy and radio- frequency ablation (RFA); by chemotherapies using cytotoxic agents or vascular targeting agents (VTA); and by external or internal radiotherapies. |
| priorityDate | 2007-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 30.